K Shahid Sukhbir
Shahid Clinic, Mumbai 400077, India.
Pharm Pat Anal. 2020 Dec;9(6):173-185. doi: 10.4155/ppa-2020-0012. Epub 2020 Dec 22.
Dengue, an illness caused by four serotypes of the dengue virus is most prevalent in Asia and Latin America. Its manifestation varies from asymptomatic cases to severe forms and even deaths and is a growing health concern. Despite attempts to curtail it, the infection continues to intensify in endemic areas and spread to new areas of the world. Development of a safe and effective vaccine and a potent antiviral drug is ongoing but so far there has been no breakthrough. Nonetheless, researchers are carrying out studies with newer vaccine candidates and antiviral moieties, and some of these hold promise for the future. The current article describes the recent patents targeted at dengue control.
登革热是由四种血清型登革病毒引起的疾病，在亚洲和拉丁美洲最为流行。其表现形式从无症状病例到严重形式甚至死亡不等，是一个日益受到关注的健康问题。尽管人们试图控制它，但这种感染在流行地区仍在加剧，并蔓延到世界新的地区。一种安全有效的疫苗和一种有效的抗病毒药物正在研发中，但迄今为止尚未取得突破。尽管如此，研究人员正在对更新的候选疫苗和抗病毒部分进行研究，其中一些对未来有希望。本文介绍了近期针对登革热控制的专利。
